Pricing Log in Create free account

enGene Therapeutics Inc (ENGN) vs Genelux Corporation (GNLX)

enGene Therapeutics Inc and Genelux Corporation are both Biotechnology companies. enGene Therapeutics Inc and Genelux Corporation are of similar size ($114.6M and $112.2M). Across the 9 metrics below, Genelux Corporation leads on 5 and enGene Therapeutics Inc on 4.

Valuation

Metric ENGN GNLX Biotechnology median
P/E n/m n/m 8.50
P/S n/m 9.67 9.71
P/B 0.51 6.75 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.91 n/m 0.64
EV/Sales n/m 8.77 9.21
Earnings yield (123.72%) (35.54%) (33.15%)
Free cash flow yield (89.30%) (26.36%) (25.50%)

Profitability

Metric ENGN GNLX Biotechnology median
Gross margin — (3.42%) 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (60.50%) (177.93%) (56.36%)
Return on assets (48.84%) (121.80%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ENGN GNLX Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (56.85%) 9.47% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENGN GNLX Biotechnology median
Debt to equity 0.11 0.00 0.00
Current ratio 10.21 2.39 4.72
Net debt to EBITDA 1.42 0.44 0.96

Dividend

Metric ENGN GNLX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ENGN GNLX Biotechnology median
Market cap 114.60m 112.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack